Multicenter, randomized, double-blind, placebo, parallel-group phase III clinical studies of recombinant human (rh) Apo2L/TRAIL in combination with vinorelbine and cispatin (NP) in patients with advanced NSCLC

Trial Profile

Multicenter, randomized, double-blind, placebo, parallel-group phase III clinical studies of recombinant human (rh) Apo2L/TRAIL in combination with vinorelbine and cispatin (NP) in patients with advanced NSCLC

Completed
Phase of Trial: Phase III

Latest Information Update: 16 May 2016

At a glance

  • Drugs Dulanermin (Primary) ; Cisplatin; Vinorelbine
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Most Recent Events

    • 03 Jun 2014 Initial results from a single study centre (n=26) presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 26 Nov 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top